| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $40.9M | $0-100.0% | $1.8M+76.5% | $1.0M | $0-100.0% | $7.6M |
| Cost of revenue | $14.0M+49.9% | $9.4M+54.6% | $6.1M+14.3% | $5.3M+49.6% | $3.5M+36.3% | $2.6M |
| Gross profit | $26.9M+16.0% | $23.2M+75.9% | $13.2M+28.6% | $10.3M-0.6% | $10.3M+106.9% | $5.0M |
| Research and development | $6.9M+45.5% | $4.8M+81.0% | $2.6M+6.2% | $2.5M-2.9% | $2.6M+53.2% | $1.7M |
| Selling, clinical, and marketing | $20.4M+66.6% | $12.2M+35.3% | $9.0M | — | — | — |
| General and administrative | $14.0M+12.7% | $12.4M+27.2% | $9.7M | — | — | — |
| Total operating expenses | $41.3M+40.5% | $29.4M+37.3% | $21.4M+2.3% | $20.9M+1.7% | $20.6M+32.9% | $15.5M |
| Loss from operations | -$14.4M-132.0% | -$6.2M+24.6% | -$8.2M+22.9% | -$10.7M-3.9% | -$10.3M+2.2% | -$10.5M |
| Other expense (income) | $451K+216.0% | -$389K+5.3% | -$410K | — | — | — |
| Loss on equity investment | $217K | $0-100.0% | $170K+154.8% | $67K | $0 | — |
| Total other expense (income) | $668K+271.8% | -$389K-61.9% | -$240K-1036.4% | -$21K-237.7% | $15K-98.6% | $1.1M |
| Loss before income taxes | -$15.1M-159.0% | -$5.8M+27.2% | -$8.0M+25.0% | -$10.7M-3.6% | -$10.3M+11.1% | -$11.6M |
| Income tax expense | $505K+38.0% | $366K+134.4% | $156K+123.1% | $70K-21.4% | $89K | — |
| Net loss | -$15.6M-151.9% | -$6.2M+24.1% | -$8.1M+24.0% | -$10.7M-3.4% | -$10.4M+10.3% | -$11.6M |
| Basic | -$0.37-131.3% | -$0.16-100.0% | $29.5M+318.3% | $7.1M+20.9% | $5.8M | — |
| Diluted | -$0.37-131.3% | -$0.16-100.0% | $29.5M+318.3% | $7.1M+20.9% | $5.8M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.